Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma; Multiple Myeloma in Relapse; Neoplasm, Plasma Cell Intervention: Biological: BCMA CAR-T cells Sponsor: Chongqing Precision Biotech Co., Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials